dc.contributor.author | Çelen, M.K. | |
dc.contributor.author | Türker, K. | |
dc.contributor.author | Öztoprak, N. | |
dc.contributor.author | Şener, A. | |
dc.contributor.author | Tuna, N. | |
dc.contributor.author | İnce, N. | |
dc.contributor.author | Tabak, F. | |
dc.contributor.author | Erdem, İlhan | |
dc.date.accessioned | 2022-05-11T14:37:22Z | |
dc.date.available | 2022-05-11T14:37:22Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 0973-7510 | |
dc.identifier.uri | https://hdl.handle.net/20.500.11776/8672 | |
dc.description.abstract | Chronic hepatitis B is a major public health problem in our country. Hepatitis A vaccination in HBV carriers who did not encounter with Hepatitis A virus is also significant. We aimed to evaluate the rate of exposure to HAV in HBsAg-positive persons, and the distribution of seronegative individuals according to age groups. Medical records of 4793 patients from 14 centers who were positive for hepatitis B surface antigen (HBsAg). A total 3514 cases (73.3%) were male and 1279 (26.7) were female. The HBsAg positive patients who were previously tested for HAV IgG at the time of firstly admitted to a center. HBsAg positive patients who were previously not tested for HAV IgG were tested and these . patients were confirmed serologically for HAV. The distribution of cases according to age were determined. In this study, 4793 HBsAg-positive patients were evaluated. The ratio of testing of anti-HAV IgG was very low during the first visit (54.2%). Seronegativity was highest in the age group under 19 years of age (26.2%) followed by 20-25 age group (15.5%) and 26-29 age group (12.5%). Testing of HAV serology should not be ignored in especially HBsAg-positive young adults and seronegative young adults should be vaccinated. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Journal of Pure and Applied Microbiology | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Anti-HAV IgG | en_US |
dc.subject | HBsAg | en_US |
dc.subject | Hepatitis A | en_US |
dc.subject | hepatitis B surface antigen | en_US |
dc.subject | immunoglobulin G | en_US |
dc.subject | adult | en_US |
dc.subject | aged | en_US |
dc.subject | Article | en_US |
dc.subject | female | en_US |
dc.subject | groups by age | en_US |
dc.subject | hepatitis A | en_US |
dc.subject | Hepatitis A virus | en_US |
dc.subject | human | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | medical record | en_US |
dc.subject | multicenter study | en_US |
dc.subject | prevalence | en_US |
dc.subject | retrospective study | en_US |
dc.subject | serology | en_US |
dc.subject | Turkey (republic) | en_US |
dc.subject | vaccination | en_US |
dc.title | The evaluation of exposure to hepatitis A virus in HBsAg-positive persons: A multicentre study from Turkey | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal of Pure and Applied Microbiology | en_US |
dc.department | Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları Ana Bilim Dalı | en_US |
dc.identifier.volume | 8 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 3063 | en_US |
dc.identifier.endpage | 3068 | en_US |
dc.institutionauthor | Erdem, İlhan | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 9335452300 | |
dc.authorscopusid | 55816781000 | |
dc.authorscopusid | 24480152400 | |
dc.authorscopusid | 23996235800 | |
dc.authorscopusid | 37081982300 | |
dc.authorscopusid | 56651969500 | |
dc.authorscopusid | 6602163658 | |
dc.identifier.scopus | 2-s2.0-84908208023 | en_US |